Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Dudley

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
Cancer Journal (Sudbury, Mass.)|August 10, 2010
Adoptive cell therapy: genetic modification to redirect effector cell specificityRichard A Morgan, Mark E Dudley, Steven A Rosenberg
The New England Journal of Medicine|September 5, 2008
Cancer immunotherapySteven A Rosenberg, Mark E Dudley, Nicholas P Restifo
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 23, 2004
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapyJuhua Zhou, Mark E Dudley, Steven A Rosenberg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 17, 2010
A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptorsShicheng Yang, Mark E Dudley, Steven A Rosenberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 9, 2004
Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanomaJuhua Zhou, Mark E Dudley, Steven A Rosenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2011
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regressionMaria R Parkhurst, John P Riley, Mark E Dudley, et al.
Blood|September 4, 2004
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapyDaniel J Powell, Mark E Dudley, Paul F Robbins, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 5, 2003
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patientsMark E Dudley, John R Wunderlich, Thomas E Shelton, et al.
Journal of Translational Medicine|April 6, 2012
Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactorRobert P T Somerville, Laura Devillier, Maria R Parkhurst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2012
Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanomaAlena Gros, Simon Turcotte, John R Wunderlich, et al.
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Cancer Journal (Sudbury, Mass.)|August 10, 2010
Adoptive cell therapy: genetic modification to redirect effector cell specificityRichard A Morgan, Mark E Dudley, Steven A Rosenberg
The New England Journal of Medicine|September 5, 2008
Cancer immunotherapySteven A Rosenberg, Mark E Dudley, Nicholas P Restifo
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 23, 2004
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapyJuhua Zhou, Mark E Dudley, Steven A Rosenberg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 17, 2010
A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptorsShicheng Yang, Mark E Dudley, Steven A Rosenberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 9, 2004
Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanomaJuhua Zhou, Mark E Dudley, Steven A Rosenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2011
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regressionMaria R Parkhurst, John P Riley, Mark E Dudley, et al.
Blood|September 4, 2004
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapyDaniel J Powell, Mark E Dudley, Paul F Robbins, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 5, 2003
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patientsMark E Dudley, John R Wunderlich, Thomas E Shelton, et al.
Journal of Translational Medicine|April 6, 2012
Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactorRobert P T Somerville, Laura Devillier, Maria R Parkhurst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2012
Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanomaAlena Gros, Simon Turcotte, John R Wunderlich, et al.
Pageof 9